Ovid: Welcome to Ovid

A Randomized, Placebo-Controlled Study to Assess Safety and Efficacy of Vardenafil 10 mg and Tamsulosin 0.4 mg vs. Tamsulosin 0.4 mg Alone in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Gacci, Mauro MD 1; Vittori, Gianni MD 1; Tosi, Nicola MD 1; Siena, Giampaolo MD 1; Rossetti, Mario Alberto MD 1; Lapini, Alberto MD 1; Vignozzi, Linda PhD 2; Serni, Sergio 1; Maggi, Mario 2; Carini, Marco 1
[Article] Journal of Sexual Medicine. 9(6):1624-1633, June 2012.

(Format: HTML, PDF)

Introduction. Safety and efficacy of tamsulosin and vardenafil are well established: however, there is no report regarding combined therapy with these drugs for lower urinary tract symptoms (LUTSs) secondary to benign prostatic hyperplasia (BPH).

Aim. To compare the safety and efficacy of tamsulosin 0.4 mg/day vs. tamsulosin 0.4 mg/day plus vardenafil 10 mg/day in patients with LUTS/BPH in a randomized trial with 12-week follow-up.

Methods. We conducted a randomized, double-blind, placebo-controlled study on 60 men with persistent storage LUTS after 2-week run-in with tamsulosin.

Main Outcome Measures. International Prostate Symptom Score (IPSS), IPSS-bother, International Index of Erectile Function, Version 5 (IIEF-5) and Over Active Bladder questionnaire (OAB-q) scores, uroflowmetry data (Qmax, Qave), and postvoiding residual urine were recorded after run-in (baseline), and 2 and 12 weeks after treatment. Differences between vardenafil and placebo at different times were calculated with unpaired samples t-test. Between-group differences in change from baseline to 2 and 12 weeks were evaluated with analysis of variance.

Results. We found a between-group significant difference from baseline to 12 weeks in the following: (i) Qmax (placebo: 0.07, vardenafil: 2.56, P = 0.034); (ii) Qave (placebo: -0.15, vardenafil: 1.02, P = 0.031); (iii) irritative-IPSS subscores (placebo: -1.67, vardenafil: -3.11, P = 0.039); and (iv) IIEF (placebo: 0.06, vardenafil: 2.61, P = 0.030). No patient reported any serious (grade >=2) adverse event (AE). There were no differences in the incidence of common, treatment-related AEs between men undergoing combined therapy or tamsulosin alone.

Conclusions. The combination of tamsulosin and vardenafil for 12 weeks was well tolerated and more effective to improve both LUTS and erectile function, as compared with tamsulosin alone. Further studies are needed to assess the role of combined therapy of phosphodiesterase type 5 inhibitors and alpha blockers in treating LUTS/BPH.